{
    "name": "midostaurin",
    "comment": "Rx",
    "other_names": [
        "Rydapt"
    ],
    "classes": [
        "Antineoplastics",
        "Tyrosine Kinase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/rydapt-midostaurin-1000156",
    "pregnancy": {
        "common": [
            "A pregnancy exposure registry monitors pregnancy outcomes in women exposed to therapy during pregnancy; Females who may have been exposed to RYDAPT during pregnancy directly or through a male partner receiving RYDAPT therapy should contact the Novartis Pharmaceuticals Corporation at 1-888-669-6682 and/or at https://report.novartis.com /",
            "Based on mechanism of action and findings in animal reproduction studies, may cause fetal harm when administered to pregnant women",
            "Administration to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicities, including late embryo-fetal death and reduced fetal birth weight, with delays in fetal growth at doses lower than the recommended human dose",
            "Pregnancy testing: Recommended for females of reproductive potential within 7 days before initiating midostaurin",
            "Infertility: Based on findings in animals, midostaurin may impair fertility in females and males of reproductive potential"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females: Drug may cause fetal harm when administered to a pregnant woman; advise females of reproductive potential to use effective contraception during treatment and for 4 months after the last dose",
                    "Males: Males with female sexual partners of reproductive potential should use effective contraception during treatment and for at least 4 months after the last dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Orally administered midostaurin and its active metabolites pass into the milk of lactating rats within 1 hr of a 30-mg/kg/day dose, with approximately 5 times more in the milk of lactating rats compared with plasma",
            "Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for at least 4 months after the last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity; reactions have included anaphylactic shock, dyspnea, flushing, chest pain, and angioedema (eg, swelling of the airways or tongue, with or without respiratory impairment)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Cases of interstitial lung disease and pneumonitis, some fatal, reported with monotherapy or in combination with chemotherapy; monitor for pulmonary symptoms; discontinue if signs or symptoms of interstitial lung disease or pneumonitis occur without an infectious etiology",
                "Prolonged severe neutropenia and thrombocytopenia in pediatric patients with AML when coadministered with strong CYP3A4 inhibitor azole antifungal ",
                "Based on its mechanism of action and findings from animal reproduction studies, midostaurin may cause fetal harm when administered to pregnant women (see Pregnancy)"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Primarily metabolized by CYP3A4",
                        "Strong CYP3A4 inhibitors",
                        "Coadministration with strong CYP3A inhibitors may increase midostaurin concentrations and risk of toxicity Consider alternative therapies that do not strongly inhibit CYP3A activity",
                        "Alternatively, if coadministered, monitor for increased risk of adverse reactions, especially during the first week of treatment",
                        "Strong CYP3A inducers",
                        "Coadministration with strong CYP3A inducers may decrease midostaurin concentrations and reduce efficacy",
                        "Avoid coadministration with strong CYP3A inducers",
                        "CYP2B6 substrates",
                        "Therapy may decrease systemic exposure of sensitive CYP2B6 substrate; dose adjustments for coadministered CYP2B6 substrate may be necessary",
                        "Substrates transporters",
                        "Coadministration of midostaurin may increase the exposure of a breast cancer resistance protein (BCRP) and organic anion transporter polypeptide (OATP)1B1 substrate; dose adjustments for the coadministered BCRP or OATP1B1 substrates may be necessary with midostaurin"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lefamulin",
            "description": {
                "common": "lefamulin will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "alfuzosin and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anagrelide",
            "description": {
                "common": "anagrelide and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apomorphine",
            "description": {
                "common": "apomorphine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "aripiprazole and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "artemether",
            "description": {
                "common": "artemether and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "artemether/lumefantrine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atomoxetine",
            "description": {
                "common": "atomoxetine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bedaquiline",
            "description": {
                "common": "bedaquiline and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "buprenorphine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "buprenorphine buccal and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine subdermal implant",
            "description": {
                "common": "buprenorphine subdermal implant and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "buprenorphine transdermal and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "buprenorphine, long-acting injection and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "crizotinib",
            "description": {
                "common": "crizotinib and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dasatinib",
            "description": {
                "common": "dasatinib and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "degarelix",
            "description": {
                "common": "degarelix and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desflurane",
            "description": {
                "common": "desflurane and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dolasetron",
            "description": {
                "common": "dolasetron and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eliglustat",
            "description": {
                "common": "eliglustat and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "entrectinib",
            "description": {
                "common": "entrectinib and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eribulin",
            "description": {
                "common": "eribulin and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fingolimod",
            "description": {
                "common": "fingolimod and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gadobenate",
            "description": {
                "common": "gadobenate and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "gemifloxacin and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gilteritinib",
            "description": {
                "common": "gilteritinib and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "granisetron",
            "description": {
                "common": "granisetron and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxyzine",
            "description": {
                "common": "hydroxyzine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoflurane",
            "description": {
                "common": "isoflurane and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lithium",
            "description": {
                "common": "lithium and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "mirtazapine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of midostaurin by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primaquine",
            "description": {
                "common": "primaquine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "sevoflurane and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "solifenacin",
            "description": {
                "common": "solifenacin and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sunitinib",
            "description": {
                "common": "sunitinib and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetrabenazine",
            "description": {
                "common": "tetrabenazine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vorinostat",
            "description": {
                "common": "vorinostat and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voxelotor",
            "description": {
                "common": "voxelotor will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arformoterol",
            "description": {
                "common": "arformoterol and midostaurin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "deutetrabenazine and midostaurin both increase  QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duvelisib",
            "description": {
                "common": "duvelisib will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix decreases levels of midostaurin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib, midostaurin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "midostaurin and fostemsavir both increase  QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "istradefylline will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osilodrostat",
            "description": {
                "common": "osilodrostat and midostaurin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and midostaurin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and midostaurin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, midostaurin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "tazemetostat will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valbenazine",
            "description": {
                "common": "valbenazine and midostaurin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "83"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "83"
        },
        {
            "name": "Hypocalcemia",
            "percent": "74"
        },
        {
            "name": "Increased ALT",
            "percent": "71"
        },
        {
            "name": "all grades",
            "percent": "66"
        },
        {
            "name": "Mucositis",
            "percent": "61"
        },
        {
            "name": "Vomiting",
            "percent": "46"
        },
        {
            "name": "Headache",
            "percent": "36"
        },
        {
            "name": "Petechiae",
            "percent": "33"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "28"
        },
        {
            "name": "Epistaxis",
            "percent": "24"
        },
        {
            "name": "Device",
            "percent": "21"
        },
        {
            "name": "related infection",
            "percent": "20"
        },
        {
            "name": "Hypernatremia",
            "percent": "20"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "3"
        },
        {
            "name": "Hyperglycemia",
            "percent": "4"
        },
        {
            "name": "Increased ALT",
            "percent": "20"
        },
        {
            "name": "grades",
            "percent": "15"
        },
        {
            "name": "and",
            "percent": "14"
        },
        {
            "name": "Hemorrhoids",
            "percent": "14"
        },
        {
            "name": "Arthralgia",
            "percent": "13"
        },
        {
            "name": "Hyperhidrosis",
            "percent": "12"
        },
        {
            "name": "Prolonged aPTT",
            "percent": "12"
        },
        {
            "name": "Renal insufficiency",
            "percent": "82"
        },
        {
            "name": "Insomnia",
            "percent": "80"
        },
        {
            "name": "Nausea",
            "percent": "68"
        },
        {
            "name": "Hyperglycemia",
            "percent": "66"
        },
        {
            "name": "Vomiting",
            "percent": "61"
        },
        {
            "name": "Lymphopenia",
            "percent": "60"
        },
        {
            "name": "Leukopenia",
            "percent": "54"
        },
        {
            "name": "Anemia",
            "percent": "50"
        },
        {
            "name": "Diarrhea",
            "percent": "49"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "40"
        },
        {
            "name": "Neutropenia",
            "percent": "39"
        },
        {
            "name": "Edema",
            "percent": "39"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "37"
        },
        {
            "name": "Hypocalcemia",
            "percent": "37"
        },
        {
            "name": "Lipase increased",
            "percent": "35"
        },
        {
            "name": "Hyperuricemia",
            "percent": "35"
        },
        {
            "name": "Increased GGT",
            "percent": "34"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "32"
        },
        {
            "name": "Hyponatremia",
            "percent": "31"
        },
        {
            "name": "Increased AST",
            "percent": "34"
        },
        {
            "name": "Increased ALT",
            "percent": "34"
        },
        {
            "name": "Fatigue",
            "percent": "30"
        },
        {
            "name": "Abdominal pain",
            "percent": "29"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "27"
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": "27"
        },
        {
            "name": "Hypoalbuminemia",
            "percent": "29"
        },
        {
            "name": "Pyrexia",
            "percent": "26"
        },
        {
            "name": "Constipation",
            "percent": "25"
        },
        {
            "name": "Headache",
            "percent": "25"
        },
        {
            "name": "Hypokalemia",
            "percent": "23"
        },
        {
            "name": "Increased creatinine",
            "percent": "23"
        },
        {
            "name": "Hyperkalemia",
            "percent": "22"
        },
        {
            "name": "Dyspnea",
            "percent": "20"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "20"
        },
        {
            "name": "Increased amylase",
            "percent": "19"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "18"
        },
        {
            "name": "Arthralgia",
            "percent": "16"
        },
        {
            "name": "Cough",
            "percent": "14"
        },
        {
            "name": "Urinary tract infection",
            "percent": "14"
        },
        {
            "name": "GI hemorrhage",
            "percent": "13"
        },
        {
            "name": "Rash",
            "percent": "13"
        },
        {
            "name": "Dizziness",
            "percent": "12"
        },
        {
            "name": "Pleural effusion",
            "percent": "11"
        },
        {
            "name": "Epistaxis",
            "percent": "11"
        },
        {
            "name": "QT prolonged",
            "percent": "11"
        },
        {
            "name": "Insomnia",
            "percent": "8"
        },
        {
            "name": "Renal insufficiency",
            "percent": "8"
        },
        {
            "name": "Hyperuricemia",
            "percent": "7"
        },
        {
            "name": "Hypertension",
            "percent": "7"
        },
        {
            "name": "Cellulitis",
            "percent": "7"
        },
        {
            "name": "Fungal infection",
            "percent": "7"
        },
        {
            "name": "Dry skin",
            "percent": "6"
        },
        {
            "name": "Weight increased",
            "percent": "5"
        },
        {
            "name": "Pleural effusion",
            "percent": "4"
        },
        {
            "name": "Thrombosis",
            "percent": "4"
        },
        {
            "name": "Tremor",
            "percent": "3"
        },
        {
            "name": "Pericardial effusion",
            "percent": "3"
        },
        {
            "name": "Hypercalcemia",
            "percent": "10"
        },
        {
            "name": "Eyelid edema",
            "percent": "10"
        },
        {
            "name": "Pneumonia",
            "percent": "9"
        },
        {
            "name": "Herpes virus infection",
            "percent": "9"
        },
        {
            "name": "Sepsis",
            "percent": "8"
        },
        {
            "name": "Hypotension",
            "percent": "7"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "6"
        },
        {
            "name": "Disturbance in attention",
            "percent": "6"
        },
        {
            "name": "Tremor",
            "percent": "6"
        },
        {
            "name": "Hematoma",
            "percent": "6"
        },
        {
            "name": "Cardiac failure",
            "percent": "6"
        },
        {
            "name": "Bronchitis",
            "percent": "6"
        },
        {
            "name": "Dyspepsia",
            "percent": "6"
        },
        {
            "name": "Weight increased",
            "percent": "5"
        },
        {
            "name": "Contusion",
            "percent": "5"
        },
        {
            "name": "Cellulitis or erysipelas",
            "percent": "5"
        },
        {
            "name": "Vertigo",
            "percent": "4"
        },
        {
            "name": "Chills",
            "percent": "4"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "4"
        },
        {
            "name": "Myocardial infarction or ischemia",
            "percent": "4"
        },
        {
            "name": "Hypersensitivity",
            "percent": "3"
        },
        {
            "name": "Mental status changes",
            "percent": "3"
        },
        {
            "name": "Pulmonary edema",
            "percent": "2"
        },
        {
            "name": "Gastritis",
            "percent": null
        },
        {
            "name": "Interstitial lung disease or pneumonitis",
            "percent": null
        }
    ]
}